These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 28895069

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
    Miyake H, Harada K, Miyazaki A, Fujisawa M.
    Med Oncol; 2015 Mar; 32(3):78. PubMed ID: 25698532
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
    Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E.
    Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
    Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B, Rainbow Group.
    Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
    [Abstract] [Full Text] [Related]

  • 16. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
    Ezz El Din M.
    Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
    Neri B, Vannini A, Tassi R, Brugia M, Rangan S, Rediti M, Cerullo C.
    Oncol Res; 2012 Jun; 20(5-6):259-64. PubMed ID: 23581233
    [Abstract] [Full Text] [Related]

  • 18. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ, Tian J, Chen X, Wang D, Li CL.
    Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
    [Abstract] [Full Text] [Related]

  • 19. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
    Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, Rini BI.
    J Clin Oncol; 2017 Jun 01; 35(16):1764-1769. PubMed ID: 28113029
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, Wang G, He ZS, Zhou LQ, Jin J.
    Chin Med J (Engl); 2011 Sep 01; 124(18):2920-4. PubMed ID: 22040503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.